Cargando…
Molecular Mechanisms of Resistance to FLT3 Inhibitors in Acute Myeloid Leukemia: Ongoing Challenges and Future Treatments
Treatment of FMS-like tyrosine kinase 3 (FLT3)-internal tandem duplication (ITD)-positive acute myeloid leukemia (AML) remains a challenge despite the development of novel FLT3-directed tyrosine kinase inhibitors (TKI); the relapse rate is still high even after allogeneic stem cell transplantation....
Autores principales: | Scholl, Sebastian, Fleischmann, Maximilian, Schnetzke, Ulf, Heidel, Florian H. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7697863/ https://www.ncbi.nlm.nih.gov/pubmed/33212779 http://dx.doi.org/10.3390/cells9112493 |
Ejemplares similares
-
Modulation of FLT3-ITD Localization and Targeting of Distinct Downstream Signaling Pathways as Potential Strategies to Overcome FLT3-Inhibitor Resistance
por: Fleischmann, Maximilian, et al.
Publicado: (2021) -
Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives
por: Fleischmann, Maximilian, et al.
Publicado: (2021) -
PB1774: PHARMACOLOGICAL STRATEGIES TO OVERCOME RESISTANCE IN AML CELL LINE MODELS HARBORING ACTIVATING FLT3-ITD AND PTPN11 MUTATIONS
por: Fleischmann, Maximilian, et al.
Publicado: (2023) -
Clinical experience with venetoclax in patients with newly diagnosed, relapsed, or refractory acute myeloid leukemia
por: Fleischmann, Maximilian, et al.
Publicado: (2022) -
Impact of treatment intensity on infectious complications in patients with acute myeloid leukemia
por: Tober, Romy, et al.
Publicado: (2022)